导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.93% | 1139/4773 |
| 近一周 | -0.70% | 1752/5467 |
| 近一月 | -6.15% | 2911/5421 |
| 近一季 | -9.69% | 3088/5238 |
| 近半年 | -1.52% | 1982/4931 |
| 近一年 | 10.57% | 997/4400 |
| 近两年 | 84.63% | 767/2954 |
| 近三年 | 48.30% | 585/2253 |
| 成立以来 | 21.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.27% 982/4961 |
20.30% 1237/5312 |
- - |
- - |
| 2025 | 34.71% 1025/4813 |
2.57% 1331/3635 |
2.21% 1753/4076 |
26.05% 1368/4524 |
1.94% 1144/4813 |
| 2024 | 8.71% 1524/3463 |
-2.47% 1365/2808 |
-5.04% 1625/3014 |
17.16% 1256/3129 |
0.19% 1254/3463 |
| 2023 | -4.14% 666/2656 |
8.42% 461/2280 |
-3.71% 874/2385 |
-4.13% 1071/2515 |
-4.23% 922/2655 |
| 2022 | -17.17% 559/2207 |
-13.67% 810/1919 |
3.65% 1115/2016 |
-10.38% 394/2113 |
3.28% 731/2208 |
| 2021 | 22.80% 137/1822 |
-0.92% 406/1255 |
11.60% 368/1330 |
6.32% 232/1466 |
4.46% 331/1822 |
| 2020 | 31.00% 510/1250 |
-3.56% 308/1028 |
18.16% 351/1067 |
10.39% 557/1164 |
4.14% 863/1184 |
| 2019 | 31.48% 467/1092 |
33.11% 146/754 |
-9.96% 706/804 |
2.30% 308/850 |
7.24% 464/918 |
| 2018 | -31.70% 503/834 |
- - |
- - |
- - |
-12.89% 491/691 |
| 2017 | 3.49% 426/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.94% 367/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华泰柏瑞中证500ETF VS. 长安沪深300非周期A(740101) |